stockrow
Saturday 7 November 2026
Export CADL’s income statement to Excel — free account
Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.
- EPS
- −477.8%
- Free cash flow
- −93.4%
- Total debt
- +525.8%
Quarter to June 2026, against a year earlier
8.66
0.62
+7.71%
Follow CADL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | 0 | 0 | — | — | — | 0 | 0.0% | 42 | 42 | 184 | +109.4% | |
| Gross margin, % | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | — | — | — | 0.00 | +100.0 pt | ||||||
| EBT | — | — | — | (8) | (18) | (36) | (19) | (38) | (55) | (38) | (89) | +29.1% | ||||||
| EBT margin, % | — | — | — | (6,592.00) | (14,144.00) | (28,899.20) | (15,035.20) | 0.00 | 0.00 | 0.00 | 0.00 | +6,592.0 pt | ||||||
| Net income | — | 0 | — | (8) | (18) | (36) | (19) | (38) | (55) | (38) | (89) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.28) | (1.52) | (1.91) | (0.65) | (1.31) | (1.74) | (0.72) | (1.41) | +17.0% | ||||||
| Cash flow | — | — | — | (0.18) | (0.78) | (1.18) | (1.09) | (1.18) | (0.85) | (0.72) | (0.76) | +26.4% | ||||||
| Capex | — | — | — | 0.00 | (0.13) | (0.10) | (0.04) | (0.01) | 0.00 | (0.01) | (0.02) | n/m | ||||||
| Free cash flow | — | — | — | (0.18) | (0.91) | (1.27) | (1.13) | (1.19) | (0.85) | (0.73) | (0.77) | +26.7% | ||||||
| Book value | — | — | — | 1.41 | (2.03) | 3.40 | 1.66 | 0.44 | 2.09 | 0.98 | 1.70 | (5.8%) | ||||||
| Shares, m | — | — | — | 29 | 12 | 19 | 29 | 29 | 32 | 53 | 61 | +10.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 661.64 | 661.64 | 1,180.70 | 408.14 | — | — | — | 5,135.81 | 728.0 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 2.30 | 1.07 | — | — | — | 5.09 | 0.8 | ||||||
| EV/Sales | — | — | — | 473.49 | 473.49 | 527.76 | 18.19 | — | — | — | 3,939.74 | 373.2 | ||||||
| EV/FCF | — | — | — | (3.43) | (3.43) | (2.74) | (0.07) | — | — | — | (8.60) | (2.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (9) | (22) | (31) | (34) | (27) | (38) | (56) | +39.6% | |||||
| Capex | — | — | — | 0 | (1) | (2) | (1) | 0 | 0 | (1) | (1) | +23.3% | ||||||
| Free cash flow | — | — | — | (5) | (11) | (24) | (33) | (35) | (27) | (39) | (57) | +39.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 44 | 30 | 80 | 66 | 23 | 66 | 112 | 191 | +17.0% | |||||
| Net debt | — | — | — | (45) | (34) | (82) | (49) | (14) | (90) | (73) | (154) | +8.4% | ||||||
| Shareholders’ equity | — | — | — | 41 | (24) | 64 | 48 | 13 | 66 | 52 | 126 | +4.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (35.90) | (42.00) | (56.67) | (22.52) | (63.82) | (74.53) | (32.91) | (56.37) | +3.0 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 52.15 | 111.90 | (178.06) | (33.61) | (125.50) | (139.56) | (64.58) | (81.84) | (116.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 50 | 65 | 76 | 42 | 38 | 55 | — | +1.9% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Dec 2022
Candel Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics, Inc. | $626.6M | 9.0× | 9.2× | +44.86% (above 0%: growing) | n/m | +106.77% (above 0%: growing) | 95.25% | 30.67% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $621.5M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| DBVT DBV Technologies S.A. | $615.8M | — (loss-making) | — | −42.86% (below 0%: shrinking) | n/m | −64.93% (below 0%: shrinking) | 100.00% | (4,043.75%) | Compare |
| CADL Candel Therapeutics, Inc. | $615.2M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | |
| HELP Cybin Inc. | $613.0M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $611.7M | — | — | +36.54% | — | −38.55% | 95.25% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
14.30%
Entities affiliated with Fidelity
13.20%
Paul B. Manning
9.60%
Estuardo Aguilar-Cordova, M.D., inf., Ph.D.
6.00%
Laura K. Aguilar
6.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement